The Safety of Therapeutic Monoclonal Antibodies: Implications
for Cancer Therapy Including Immuno-Checkpoint Inhibitors

J 2016

The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors

DEMLOVÁ, Regina, Dalibor VALÍK, Radka OBERMANNOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ

Basic information

Original name

The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors

Authors

DEMLOVÁ, Regina (203 Czech Republic, guarantor, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution) and Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution)

Edition

Physiological Research, Praha, Fyziologický ústav AV ČR, 2016, 0862-8408

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.461

RIV identification code

RIV/00216224:14110/16:00093104

Organization unit

Faculty of Medicine

UT WoS

000392029200005

Keywords in English

Cancer treatment; Monoclonal antibodies; Immune checkpoint inhibitors; Immune related adverse events

Abstract

V originále

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

DEMLOVÁ, Regina, Dalibor VALÍK, Radka OBERMANNOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. Physiological Research. Praha: Fyziologický ústav AV ČR, 2016, vol. 65, Suppl. 4, p. "S455"-"S462", 8 pp. ISSN 0862-8408.

@article{1369176,
   author = {Demlová, Regina and Valík, Dalibor and Obermannová, Radka and Zdražilová Dubská, Lenka},
   article_location = {Praha},
   article_number = {Suppl. 4},
   keywords = {Cancer treatment; Monoclonal antibodies; Immune checkpoint inhibitors; Immune related adverse events},
   language = {eng},
   issn = {0862-8408},
   journal = {Physiological Research},
   title = {The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors},
   volume = {65},
   year = {2016}
}

TY  - JOUR
ID  - 1369176
AU  - Demlová, Regina - Valík, Dalibor - Obermannová, Radka - Zdražilová Dubská, Lenka
PY  - 2016
TI  - The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors
JF  - Physiological Research
VL  - 65
IS  - Suppl. 4
SP  - "S455"-"S462"
EP  - "S455"-"S462"
PB  - Fyziologický ústav AV ČR
SN  - 08628408
KW  - Cancer treatment
KW  - Monoclonal antibodies
KW  - Immune checkpoint inhibitors
KW  - Immune related adverse events
N2  - Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulate immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on their mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.
ER  -

DEMLOVÁ, Regina, Dalibor VALÍK, Radka OBERMANNOVÁ and Lenka ZDRAŽILOVÁ DUBSKÁ. The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. \textit{Physiological Research}. Praha: Fyziologický ústav AV ČR, 2016, vol.~65, Suppl. 4, p.~''S455''-''S462'', 8 pp. ISSN~0862-8408.

Detailed Information on Publication Record